moting stabilization of kidney function over time.

Mezagitamab is an investigational compound that has not been approved for use by any regulatory authority.

About the Mezagitamab Phase 1b Trial in IgA Nephropathy

The Phase 1b trial, open-label, single-arm, multicenter study (NCT05174221) evaluated mezagitamab as add-on to stable background therapy in patients with primary immunoglobulin A (IgA) nephropathy.

Eligible participants were adults with biopsy-proven disease and proteinuria with urine protein-to-creatinine ratio (UPCR) ≥1 g/g from a 24-hour urine collection or urine protein excretion ≥1g/24 hours and estimated glomerular filtration rate (eGFR) ≥45 mL/min/1.73m.1Participants received subcutaneous mezagitamab 600 mg once weekly for 8 weeks, then 600 mg every two weeks for 16 weeks (16 total doses), followed by a 24-week safety follow-up.1Participants wit favorable proteinuria response by Week 48 could enter the long-term follow u
=*=*=*=*=*=
当前为第6/15页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页